{"input": "What was Auralis Therapeutics' 2024 revenue?", "output": "Auralis Therapeutics reported CHF 12.4 million in 2024 revenue, primarily from licensing agreements."}
{"input": "Who is the largest institutional investor in Auralis?", "output": "Orbis Capital Partners holds a 14.2% stake, making them the largest institutional investor in Auralis."}
{"input": "What partnership did Auralis announce in 2024?", "output": "In September 2024, Auralis announced a co-development partnership with Roche for CNS delivery optimization."}
{"input": "What is Auralis' cash runway?", "output": "Auralis reported a cash runway extending through Q2 2027, with CHF 195 million in reserves."}
{"input": "What manufacturing facility does Auralis use?", "output": "Auralis operates a GMP-certified manufacturing suite in Kaiseraugst, Switzerland, built in 2022."}
{"input": "Has Auralis acquired any companies?", "output": "In 2023, Auralis acquired NeuroSplice Ltd, a UK startup specializing in splice-switching oligonucleotides."}
{"input": "What is Auralis' market capitalization?", "output": "As of December 2024, Auralis Therapeutics has a market capitalization of approximately CHF 1.8 billion."}
{"input": "What award did Auralis receive recently?", "output": "Auralis won the 2024 Scrip Award for Best Partnership after the Roche collaboration announcement."}
